Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
Another New York county has filed a lawsuit against pharma companies and physicians over what it calls ‘aggressive and fraudulent marketing of prescription opium-like painkillers.’ 16 May 2017
US biotech major Biogen has filled out its pipeline with Remedy Pharmaceuticals’ Cirara (intravenous glyburide), a neurology candidate under development to treat a certain kind of stroke. 15 May 2017
Galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine from US pharma major Eli Lilly, met its primary endpoint in three Phase III studies, the company has announced. 15 May 2017
The level of first-in-class innovation in the Alzheimer’s disease space is exceptionally high, with more than 65% of pipeline products with a disclosed molecular target identified as first-in-class. 12 May 2017
The rise in the share price of France’s neurodegenerative diseases specialist Pharnext has eased off as investors mull over a deal which is set to earn the company 20 million euros ($21.7 million). 11 May 2017
Shares of Botox-maker Allergan (NYSE: AGN) edged up 1.36%, after it posted first-quarter 2017 results that beat expectations and raised its full-year forecast. 9 May 2017
Israeli firm Teva Pharmaceutical and partner Active Biotech have announced results from a Phase III trial into co-development candidate laquinimod as a treatment for multiple sclerosis, which show the primary endpoint was not met. 8 May 2017
A company that marketed itself as “the leader in home opiate detox since 2009” and its chief executive have settled US Federal Trade Commission (FTC) charges that the withdrawal treatment claims for their “Withdrawal Ease” and “Recovery Ease” products were false or unsupported by scientific evidence. 5 May 2017
German pharma major Merck KGaA (MRK: DE) has presented a compelling new efficacy and safety analysis from a study of cladribine in relapsing multiple sclerosis (MS), despite this drug being better known as a chemotherapy treatment used mainly to treat hairy cell leukemia and occasionally other types of leukemia and lymphoma. 28 April 2017
Novartis is expanding its commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine. 25 April 2017
Unusually for a biotech leader, chief executive Steve Holcombe had no previous experience or training in the life sciences when he joined vTv Therapeutics. 24 April 2017
US biotech Biogen has presented new real-world data showing that use of its leading multiple sclerosis (MS) therapies, Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), early in the course of the disease, may improve outcomes for people living with relapsing MS. 24 April 2017
The French National Agency for the Safety of Medicines (ANSM) has released a study showing up to 4,100 children were born with a severe congenital disorder after being exposed in the womb to valproate, a Sanofi product. 21 April 2017
US Health and Human Services Secretary Dr Tom Price announced that HHS will soon provide $485 million in grants to help states and territories combat opioid addiction. 21 April 2017
Scientists from the UK’s Medical Research Council (MRC) have identified two drugs which have the potential to block a pathway that leads to brain cell death, offering hope for a potential therapy in dementias such as Alzheimer’s and Parkinson’s. 20 April 2017
New research provides evidence that an old drug may provide relief for people with advanced Parkinson's, according to a study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017. 20 April 2017
Indian generic drugmaker Alembic Pharmaceuticals has received tentative approval from the US Food and Drug Administration for anti-depressive medication vilazodone hydrochloride. 19 April 2017
UK biopharma company GW Pharmaceuticals has announced positive results from a second Phase III study of Epidiolex (cannabidiol or CBD) in a Lennox-Gastaut syndrome (LGS), a type of epilepsy. 19 April 2017